Abstract

Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.

Original languageEnglish (US)
Pages (from-to)949-952
Number of pages4
JournalCancer Discovery
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Drug Discovery
Epigenomics
Lung Neoplasms
Neoplasms
Therapeutics
In Vitro Techniques
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Oncology

Cite this

Developing EZH2-targeted therapy for lung cancer. / Frankel, Arthur E.; Liu, Xin; Minna, John D.

In: Cancer Discovery, Vol. 6, No. 9, 01.09.2016, p. 949-952.

Research output: Contribution to journalArticle

@article{b16a6462afce4fd0aaf5b369b87d04bf,
title = "Developing EZH2-targeted therapy for lung cancer",
abstract = "Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.",
author = "Frankel, {Arthur E.} and Xin Liu and Minna, {John D.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1158/2159-8290.CD-16-0800",
language = "English (US)",
volume = "6",
pages = "949--952",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Developing EZH2-targeted therapy for lung cancer

AU - Frankel, Arthur E.

AU - Liu, Xin

AU - Minna, John D.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.

AB - Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.

UR - http://www.scopus.com/inward/record.url?scp=85012024585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012024585&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0800

DO - 10.1158/2159-8290.CD-16-0800

M3 - Article

C2 - 27587466

AN - SCOPUS:85012024585

VL - 6

SP - 949

EP - 952

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 9

ER -